	_											
FÖRM (REV. 7	PTO-139 (-2005)	90 (Modified) U.S. PATENT AND TRADEM	ARK OFFICE; U.S. DEPARTMENT OF COMMERCE	ATTORNEY'S DOCKET NUMBER								
-1			TO THE UNITED STATES	PB60320USW								
		DESIGNATED/ELECTE	U.S. APPLICATION NO. (If known, see 37 CFR 1.5)									
CONCERNING A SUBMISSION UNDER 35 U.S.C. 371												
INTE		ONAL APPLICATION NO.	INTERNATIONAL FILING DATE	PRIORITY DATE CLAIMED								
T171 F		CT/EP2004/006592	6/17/04	6/19/03								
		NVENTION L-2-OXO-3-SHLFONYLAMINO	D-PYROLIDINE DERIVATIVES AND REI	LATED COMPOUNDS AS FACTOR XA								
			OF ACUTE VASCULAR DISEASES									
APPL	ICAN	T(S) FOR DO/EO/US										
Alan David BORTHWICK, Chuen CHAN, Henry Anderson KELLY, Savvas KLEANTHOUS, Andrew McMurtrie MASON, Nigel Stephen WATSON												
Applic	ant he	erewith submits to the United State	s Designated/Elected Office (DO/EO/US) the fo	ollowing items and other information:								
1.	$\boxtimes$	This is a FIRST submission of ite	ms concerning a submission under 35 U.S.C. 3	371.								
2.		This is a SECOND or SUBSEQUENT submission of items concerning a submission under 35 U.S.C. 371.										
3.	$\boxtimes$	This is a <b>SECOND</b> or <b>SUBSEQUENT</b> submission of items concerning a submission under 35 0.5.C. 371.  This is an express request to begin national examination procedures (35 U.S.C. 371(f)). The submission must include items (5), (6), (9) and (24) indicated below.										
4.	$\boxtimes$	The US has been elected (Article	31).									
5.	. 🛛	A copy of the International Application as filed (35 U.S.C. 371 (c)(2))										
		a.  is attached hereto (required only if not communicated by the International Bureau).										
		b.  has been communicated by the International Bureau.										
		c. 🗵 is not required, as the application was filed in the United States Receiving Office (RO/US).										
6.		An English language translation of the International Application as filed (35 U.S.C. 371(c)(2)).										
		a.  is attached hereto.										
		b.   has been previously sub	omitted under 35 U.S.C. 154(d)(4).									
7.		Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371 (c)(3))										
		a.   are attached hereto (required only if not communicated by the International Bureau).										
		b.  have been communicated by the International Bureau.										
		c. $\square$ have not been made; however, the time limit for making such amendments has NOT expired.										
		d. $\square$ have not been made and will not be made.										
8.		An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).										
9.	$\boxtimes$	An oath or declaration of the inventor(s) (35 U.S.C. 371 (c)(4)).										
10.		An English language translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371 (c)(5)).										
11.	$\boxtimes$	A copy of the International Prelim	inary Examination Report (PCT/IPEA/409).									
12.	$\boxtimes$	A copy of the International Search Report (PCT/ISA/210).										
It	ems 1	3 to 23 below concern documen	t(s) or information included:									
13.	$\boxtimes$	An Information Disclosure Stater	nent under 37 CFR 1.97 and 1.98.									
14.		An assignment document for reco	ording. A separate cover sheet in compliance w	vith 37 CFR 3.28 and 3.31 is included.								
15.	$\boxtimes$	A FIRST preliminary amendment.										
16.		A SECOND or SUBSEQUENT pr	eliminary amendment.									
17.		A substitute specification.										
18.		A power of attorney and/or chang	e of address letter.									
19.		A computer-readable form of the	sequence listing in accordance with PCT Rule	13ter.2 and 37 CFR 1.821 - 1.825.								
20.		A second copy of the published Ir	nternational Application under 35 U.S.C. 154(d)	(4).								
21.		A second copy of the English lang	guage translation of the International Application	n under 35 U.S.C. 154(d)(4).								
22.	$\boxtimes$	Express Mail Label No. EV	332130835US									
I												

LAP20 Rec. of 2005

PTO-1390 (Rev. 07-2005)

Approved for use through 3/31/2007. OMB 0651-0021

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

U.S. APPLICATION NO (if known, see 37 CFR 1.5)	INTERNATIONAL APPLICATION NO.	ATTORNEY'S DOCKET NUMBER
INIELARIA	PCT/EP2004/006592	PB60320USW
23. Other items or information:		

**PCT Request PCT Publication Coverpage** 

The following	fees have been	submitted					CALCULATIONS	PTO USE
	ational fee	00 \$	\$300.00					
25. Examina If the written opini prepared by IPEA All other situations	/US indicates all	ort \$	\$200.00					
Search fee (37 CF as an International Sear	onof the ISA/US indicates all clais FR 1.445(a)(2)) hational Searching the Report preparecommunicated to	00 00 00	\$400.00					
	OF 24, 25 and	\$	\$900.00					
	e for specification ting in compliance lectronic medium 50 for each addit	g 						
Total Sheets	Extra Sheets		Number of each additional 50 or RATE fraction thereof (round <b>up</b> to a whole					
70 - 100 =	0 /50 =	İ	. 0		× \$250.00	9	\$0.00	
			e search fee, examinatio of the national stage (37			. §	3	
CLAIMS	NUMBER F	FILED	NUMBER EXTRA RA		RATE			
Total claims	9	- 20 =	0	х	\$50.00	) \$	\$0.00	
Independent clain	ns 3	- 3=	0	х	\$200.00	\$	\$0.00	
MULTIPLE DEPE	NDENT CLAIMS	(if applica	ble)	+	\$360.00	9	\$0.00	
		TC	TAL OF ABOVE C	ALC	ULATIONS	s = [s	\$900.00	
Applicant cla	ims small entity s	tatus. See	37 CFR 1.27. Fees abo	ve are	reduced by	\$	\$0.00	
				S	SUBTOTAL	. = \$	\$900.00	
Processing fee of the earliest claims	\$130.00 for furnied priority date (3	, 8	\$0.00					
		= \$	\$900.00	•				
Fee for recording accompanied by a		+ \$	\$0.00					
		= \$	\$900.00					
						1	Amount to be	\$

0/561545

PTO-1390 (Rev. 07-2005)
Approved for use through 3/31/2007. OMB 0651-0021
U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number. to cover the above fees is enclosed 19 DEC 2005 a. A check in the amount of \$ Please charge my Deposit Account No. 07-1392 in the amount of \$ A duplicate copy of this sheet is enclosed. M The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment . A duplicate copy of this sheet is enclosed. to Deposit Account No. 071392 information should not be included on this form. Provide credit card information and authorization on PTO-2038. NOTE: Where an appropriate time limit under 37 CFR 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the International Application to pending status. SEND ALL CORRESPONDENCE TO: Amy H. Fix NAME **Customer Number** 42,616 23347 REGISTRATION NUMBER 2005 14 Dec. DATE

Rec'd PCT/PTO 19 DEC 2009 Docket No. **CERTIFICATE OF MAILING BY "EXPRESS MAIL" (37 CFR 1.10)** PB60320USW Applicant(s): Borthwick et al. Customer No. **Group Art Unit** Application No. Filing Date Examiner 23347 1-PHENYL-2-OXO-3-SULFONYLAMINO-PYROLIDINE DERIVATIVES AND RELATED COMPOUNDS AS FACTOR XA INHIBITORS FOR THE TREATMENT OF ACUTE VASCULAR DISEASES Invention: I hereby certify that the following correspondence: Transmittal Letter to the DO/EO/US Concerning a filing under 37 U.S.C. 371 (Identify type of correspondence) is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on Allyson K. Jacobs (Typed or Printed Name of Person Mailing Correspondence) (Signature of Person Mailing Correspondence)

Note: Each paper must have its own certificate of mailing.

EV332130635US